Crystal gazing the new biotechnologies: several scientific, conceptual, and financial challenges face biotechnology if it is to overcome thus far intractable problems in human disease and agriculture
Article Abstract:
Article details a history of progress in controlling disease and utilizing technology in other areas such as agriculture.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Validating a business model
Article Abstract:
ValiGene S.A. (Paris, France) and Kimeragen (Newtown, PA) have merged under the ValiGen name to offer functional genomics services.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Bayer lapse exposes pharma's vulnerability
Article Abstract:
Bayer's withdrawal of its cholesterol reducing drug cerivastatin is problematic for the company, but is also an example of the cracks that are beginning to show in the business of major pharmaceutical companies.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Dislikes, distastes and the undesired self: conceptualising and exploring the role of the undesired end state in consumer experience
- Abstracts: Information technology as competitive advantage: the role of human, business, and technology resources. Competitive advantage: logical and philosophical considerations
- Abstracts: Self-service technology effectiveness: the role of design features and individual traits. The impact of technology on the quality-value-loyalty chain: a research agenda
- Abstracts: Ethical leadership in insurance and financial services. The gathering storm. Whistle-blowing in the financial services profession
- Abstracts: Biotech companies adapt to big pharma mergers. Genzyme acquires Cell Genesys. Demise of the life science company begins